In 2009, the GuideLiner Catheter revolutionized the concept of guide extension, creating new possibilities in...
TCT
This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures.
-
-
From a cardiovascular device innovation standpoint, the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference...
-
Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology has been replaced with a much more somber, cautiously optimistic tone at the...
-
Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston Scientific, explains...
News | Angiography | October 17, 2018
October 17, 2018 — Shimadzu Medical Systems USA and Change Healthcare have entered a partnership through which...
The cardiovascular innovation cycle, presented by TCT Course Director Martin Leon, M.D., at TCT 2018.
Blog | Cath Lab | October 16, 2018
There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on...
An example of the new transesophageal echo (TEE) visualization technology called TrueVue was shown at TCT 2018 for the first time. Philips’ new photo-realistic rendering is designed to offer a surgical view of cardiac structures to aid transcatheter procedural navigation. The technology also allows the lighting source to be moved around and even behind the anatomy, as demonstrated here. This video, included as part of the most innovative technologies video at TCT 2018, went viral when posted on social media during TCT 2018, and was viewed more than 167,000 times.
Blog | TCT | October 15, 2018
From a cardiovascular device innovation standpoint, the 2018...
Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward.
Feature | Stents Bioresorbable | October 12, 2018 | Dave Fornell, Editor
Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology...
A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES.
News | Stents Bioresorbable | October 12, 2018
October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom...
Videos | October 11, 2018
A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president,...
The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the CathWorks FFRangio angiography imaging derived fractional flow reserve (FFR-angio) technology matched the performance of wire-based FFR measurements.
News | FFR Technologies | October 04, 2018
October 4, 2018 — The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the...
A series of procedural images of a pulmonary artery denervation for CpcPH from the PADN-5 trial.
News | Hypertension | October 04, 2018
October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and...
The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.
News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials...
Videos | TCT | October 03, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the...
News | Heart Valve Technology | October 03, 2018
October 3, 2018 — A high number of patients in a study who underwent...
News | Hypertension | October 02, 2018
October 2, 2018 — Two-year results of the Moderato I Study demonstrated immediate, substantial and sustained...
